Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Sri Ramachandra Institute of Higher Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Pediatric patients diagnosed with Acute Lymphoblastic Leukemia 2. Both male and female patients between the age group of 0 -18 years 3. Patients who are categorized as high-risk, intermediate-risk, and relapse based on the protocol 4. Patients who are being prescribed Intravenous (I.V) Methotrexate (500mg/m2-5gm/m2)
Exclusion criteria
Exclusion criteria: 1. Patients with other types of malignancies 2. Patients who are being prescribed oral Methotrexate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study will predict the genetic variant gene responsible for the development of methotrexate-induced toxicity in ALL patients, which will be useful in tailoring the doses of Methotrexate for this population.Timepoint: After 24 hrs of methotrexate administration genetic analysis will be carried out | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum concentration leading to Methotrexate induced toxicities will be identifiedTimepoint: Patients serum concentration will be estimated at baseline, after 24 and 48 hrs after Methotrexate administration | — |
Countries
India
Contacts
Public ContactDr Vanitha Rani N
Sri Ramachandra Institute of higher education and Research
Outcome results
None listed